We analyzed 270 cases of fungal endocarditis (FE) that occurred over 30 years. Vascular lines, non-cardiac surgery, immunocompromise and injection drug abuse are increasing risk factors. Delayed or mistaken diagnosis (82% of patients), long duration of symptoms before hospitalization (mean ‫ע‬ standard deviation, days) and extracardiac manifestations were characteristic. From 1988 onwards, 72% of patients were 32 ‫ע‬ 39 diagnosed preoperatively, compared with 43% before 1988 ( ). The fungi most commonly isolated P p .0001 were Candida albicans (24% of patients), non-albicans species of Candida (24%), Apergillus species (24%), and Histoplasma species (6%); recently-emerged fungi accounted for 25% of cases. The mortality rate was 72%. Survival rates were better among patients who received combined surgical-antifungal treatment, were infected with Candida, and had univalvular involvement. Improvement in the survival rate (from !20% before 1974 to 41% currently) coincided with the introduction of echocardiography and with improved diagnostic acumen. Fungal endocarditis recurs in 30% of survivors. It is recommended that fungal endocarditis be diagnosed early through heightened diagnostic acumen; that patients be treated with combined lipid-based amphotericin B and early surgery; and that patients be followed up for у4 years while on prophylactic antifungal therapy. Previous reviews of fungal endocarditis (FE) published 120 years ago [1] [2] [3] [4] [5] indicated substantial related morbidity and mortality. Striking changes have since occurred in mycologic epidemiology, diagnostics, and therapeutics, which have made the challenge of management more dynamic. The objective of this study is to present an overview of the clinical profile, presumed risk factors, fungal organisms, therapeutic managements, and outcome of well-documented cases of FE
METHODS
In cooperation with a reference librarian, we conducted a literature search on the Ovid-Medline database using the key words "endocarditis," "mycoses," "fungi" (in general), and "fungi" (specific human pathogen names) to identify publications that describe FE in humans during the period 1965-1995.
High-quality case reports containing adequate information were eligible for analysis if the article met the following criteria: it was written in English; it described human cases; it provided information relating to demography, risk factors, clinical features, mycologic results, findings of echocardiography, surgery, or autopsy (pooled cases with limited or summary findings or data or general reviews were not acceptable); it provided evidence of mycologic diagnosis (i.e., positive fungal culture from blood, cardiac vegetation, or distal embolus or histologic features of fungal disease); it used the Beth-Israel or Duke definitions for infective endocarditis; and it described the outcome. Care was taken to exclude cases likely to reflect duplicate reporting.
The FrameMaker version 5.0.1 (Adobe) word processing package was used to design data collection forms. Articles were reviewed and data abstraction performed independently and in duplicate (by M.E. and H.A.). The final data for analysis was unanimous for each case. A SIR 3.2 data entry and validation program was used to verify information collected. Data were entered twice to correct any errors made during the first data entry, and data cleaning was performed before analysis.
A presumed risk factor was defined as the documentation of a feature generally accepted to contribute to the development of infective endocarditis, such as valvular heart disease [6] , and to invasive fungal infection, such as immunosuppression [7] . A patient could have 11 risk factor, and risk factors could be unrelated to each other (e.g., injection drug abuse and diabetes) or related (e.g., immunodeficiency disease, such as systemic lupus, and steroid therapy).
We estimated durations of survival using the Kaplan-Meier technique and compared them using a 2-side log rank test. A logistic regression module of SPSS software was used to examine the influence of 19 risk factors, sex, and age on death. We did not perform an advanced in-depth analysis of confounders and interactions of risk factors and treatments.
RESULTS
A total of 490 articles were initially identified, but 270 were excluded because they were in a language other than English ( ), had inadequate documentation ( ), were n p 129 n p 102 nonclinical publications ( ), or were general reviews n p 32 ( ). Included in the analysis were 220 articles; 193 of these n p 7 described a single patient, although 1 published in 1976 described 7. We also analyzed 270 case reports that met the inclusion criteria, but not all of them provided all the information we needed to complete the data form.
From these articles we obtained data on 184 male patients and 83 female patients (male-to-female ratio, 2.22), and 3 patients whose sex was not specified. The mean age ‫ע(‬ SD) of adult patients was years (range, 13-77 years), and 44.3 ‫ע‬ 14.3 of children was years (range, 1 month to 12 years). 2.90 ‫ע‬ 3.81 Risk factors. All but 6 patients had у1 risk factor. Fiftysix (21%) of 270 patients had 1 risk factor; 77 (29%) had 2 risk factors; 75 (28%) had 3; and 56 (21%) had 4-7. The average number of risk factors per patient was 2.5. The risk factors are summarized in table 1; they include previous valvular surgery, antibiotic use, rheumatic heart disease, and nonvalvular major surgery. We identified 82 unique patterns of risk factors and 20 patterns that were shared by у2 patients (table 2) .
The spectrum of immunosuppressive conditions among the patients in the study included the following: infection with HIV, diabetes mellitus, malignancy, neutropenia, organ transplantation, and treatment with corticosteroids (42 of 45 patients who had immunosuppressive therapy as a stem risk factor) or with other immunosuppressive drugs (cyclosporin A, azathioprine, monoclonal CD3 antibody [OKT3], and cyclophosphamide).
Valvular disease and valvular surgery. Of the patients we studied, 174 (64%) had у1 "valvular" risk factor-that is, a history of previous valvular surgery, bacterial endocarditis, rheumatic heart disease, nonrheumatic heart disease, or prolapsed mitral valve. Of the 146 patients with previous valvular surgery, 23 (16%) had undergone the procedure 11 time; 135 had replacement valves (74 of which were with nonbiological materials); and 18 of 146 patients did not present with FE until 12 years later.
Anatomic site of FE. The anatomic site of the vegetations could be determined in 257 patients; the aorta was the most common site (table 3) . Ring abscesses were associated with aortic valve FE in 25 of 55 patients classified as having FE of the aortic and another valve, but were associated with only 1 patient with mitral valve FE. Other sites included the pulmonary area (7 patients) and the endocardium (12 patients).
Of 112 patients who underwent surgery as part of the management for FE, there were 56 with sufficient published details to precisely correlate the anatomic location of the fungal vegetations noted at surgery with the site of previous valvular surgery. Twenty-seven (90%) of 30 patients who had previous aortic valvular surgery had FE that was confined to the aortic valve, whereas 3 (10%) had vegetations only on the mitral valve. Nine (64%) of 14 patients with previous mitral valve surgery were found to have FE on the same valve, but 5 (36%) had vegetations on the aortic valve only, and the valves operated on previously were free of FE. Of the 12 patients with previous surgery to other valves, fungal vegetations were found on the corresponding prosthetic valves in only 7 (58%).
We identified 36 patients without previous valve surgery whose only risk factor for right-side endocarditis (i.e., without existing known valvular disease) was injection drug abuse, total parenteral nutrition, or central iv line insertion. These patients might have been expected to be at risk for FE of tricuspid valves, pulmonary valves, or both. However, in this group of patients, FE occurred on these valves in only 8 (22%) of 36 patients (pulmonary, ; tricuspid, ). n p 2 n p 6 Substantial changes in the percentage contribution of the most common risk factors were observed over the years. These are shown in the smoothed incidence curves in figure 1. The incidence of vascular lines, surgery other than cardiac surgery, immunocompromised patients, and injection drug abuse showed increases, in contrast to the decline in incidence of previous valve surgery, antibiotic use, rheumatic heart disease, previous bacterial endocarditis, and other valve disease.
Clinical features of presentation and diagnosis. Thirtyfour distinct presenting features could be identified. The 6 most common were as follows: fever ( ), changing or new n p 202 heart murmurs ( ), major peripheral embolization n p 137 A total of 261 patients had у1 of the 6 most common symptoms. The mean number of symptoms was 6 per patient (range, 0-13 symptoms). For the 270 patients, there were 208 combinations of symptoms, 188 of which were unique. Thirteen patients had fever only; 10 had fever with major peripheral embolization; and 9 had fever with some other symptom.
Embolization of major arterial vessels that resulted in focal ischemia occurred in 154 sites in 122 (45%) of 270 patients (table 4) . Major limb vessel occlusion of the femoral artery division was seen in 42 patients. Upper limb ischemic phenomena were seen in only 8 patients. Focal cerebrovascular symptomatic involvement was documented in 47 patients, and this was expressed mainly as hemiplegia, facial palsy, and amaurosis fugax or other transient ischemic attacks. A further 24 patients had nonfocal neurological features, namely confusion, 
Other 47 (18) Not specified 15 (6) seizures, or altered consciousness. Thus a total of 71 (26%) of 270 patients had prominent central neurologic presentations. FE was among the listed differential presenting diagnoses for only 48 (18%) of 270 patients. Subacute bacterial endocarditis was the most common initial misdiagnosis and was cited for 111 (41%) of 270 patients. A wide range of other incorrect diagnoses at presentation was mentioned for the remaining 111 patients, including fever of unknown origin, bacterial sepsis, valvular incompetence, renal failure, peripheral embolism, and stroke.
Duration of symptoms before diagnosis. Two hundred patients developed FE at home, and 69 patients developed the disease while hospitalized (for 1 patient, this information was not given). Of the 200 patients who developed FE at home, there were 129 patients for whom adequate information was reported on the duration of symptoms. The time from the first symptom to hospital admission ranged from 1 day to 1 year. The distribution showed peaks at regular intervals of 1 day, 1 week, 2 weeks, 3 weeks, 6 weeks, 2 months, and 3 months. The tail of the distribution extended past 4 and 5 months, with 4 patients each reporting symptoms for that period of time. There were 4 patients with symptoms that lasted 9 months to 1 year. If these 4 patients are excluded, the duration of mean ‫ע‬ SD symptoms was days; median, 21 days;
). An-32 ‫ע‬ 39 n p 125 other 69 patients were already hospitalized for the management of other illnesses; the duration of symptoms before diagnosis was described for 66 of these, and it ranged from 1 day to 1 year. This distribution was smoother-without peaks but with a gap between 5 months ( ) to 7 months followed by 1 n p 64 (1, 1965Ϫ1971; 2, 1972-1979; 3, 1980-1995; and 4, 1988-1995) . Curves are smoothed. (2) year ( ). If the outliers at 7 months and 1 year are excluded, n p 5 the mean time (‫ע‬SD) from the first symptom to hospital admission was days (median, 27 days; ). Com-34 ‫ע‬ 31 n p 64 plete information regarding duration of hospitalization was available for 236 hospitalized patients. Hospitalization time was 1-395 days before the diagnosis of FE; 91% of the patients were hospitalized for up to 2 months before diagnosis. The mean time (‫ע‬SD) to diagnosis for these 214 patients was 17 ‫ע‬ 16 days.
The diagnosis of FE was made preoperatively for 128 patients (47%), perioperatively for 40 (15%), and was only made at postmortem examination for 92 (34%). The time was not clearly specified for 10 patients. However, over the years, there was an increasing proportion of the patients for whom the diagnosis was made earlier (i.e., preoperatively): 43% of patients before 1988 and 72% from 1988 onwards. This change in the timing of diagnosis was statistically significant ( ). P p .0001
Echocardiography. Echocardiography was used as a diagnostic tool for 105 patients (101 patients after 1975). There were 111 pretreatment examinations performed. For 82 of these 105 patients, the distinction between transthoracic and transesophageal modes was not specified. Eighty-six of 111 examinations of 84 patients showed evidence of FE (77% sensitive), and 25 (21 patients) did not (23% false negativity). Thirty-nine vegetations identified by echocardiography were described categorically for 37 patients as either small, medium, or large. Thirty-seven of these patients had large vegetations on у1 valve. Two patients had large vegetations on 2 valves. The most common site for a vegetation seen via echocardiography was the aortic valve, and all of these were described as large. Only 35 of the vegetations were described categorically. Four vegetations were described both in millimeters and categorically: 2 tricuspid vegetations (40 and 100 mm), 1 mitral vegetation (20 mm), and 1 pulmonary vegetation (8 mm). Nine other patients had vegetations described only in millimeters, as follows: 2 aortic vegetations (3 and 8 mm); 4 mitral (2 that were 20 mm, 1 that was 14 mm, and 1 that was 5 mm); 2 tricuspid (15 and 10 mm); and 1 endocardium (10 mm).
Laboratory data.
Chemistry and hematologic profiles were published for a minority of patients. Source of mycologic diagnosis. All 270 patients had either a blood culture, cardiac vegetation culture, or histologic examination of a valve performed. A positive mycologic diagnosis was made for 139 of 260 patients by blood cultures (54% sensitivity). Results of blood cultures were positive for specimens obtained preoperatively from 118 patients (85%), for specimens obtained postoperatively for 5 patients (4%), and for specimens Of 270 patients, 145 had all 3 of these diagnostic tests performed, and 44 had positive results on all 3. Only 2 patients were negative by all 3 tests. For 21 patients, results were positive for culture of blood specimens and histologic examination of a valve, but negative for culture of cardiac vegetation specimens. For 4 patients, results of culture of blood specimens was positive but results of culture of cardiac vegetation specimens and histologic examination of a valve were negative. Table 5 presents 3-way correlations between these tests.
In addition, there were 77 patients with accessible peripheral large arterial vessel embolization; 65 of these underwent embolectomy. Histologic examination revealed that 41 of 65 patients (63% sensitivity) had microscopical features compatible with fungal infection.
For 27 patients (10%) with unexplained fever and no other features of FE, candidemia had been documented as part of a diagnostic work-up at a mean time of 15 weeks (range, 1-52 weeks) before diagnosis of FE. Eleven of these 27 patients (41%) received no systemic antifungal treatment. Serologic testing aided the diagnosis for only 46 patients (17%), and positive results were reported for 37 (80%) of 46.
Pathogens. All patients but 3 were reported as having a single fungal pathogen. These 3 had polymicrobial fungal infections: Candida parapsilosis and Candida albicans, Candida tropicalis and C. parapsilosis, and C. albicans and Aspergillus species. Table 6 presents data on the pathogens isolated by the year the study was published. Candida were isolated for 142 (53%) patients. The ratio between non-albicans species of Candida and C. albicans species was 1.2. C. parapsilosis comprised the majority of the identifiable non-albicans species of Candida Aspergillus species were identified for 66 (25%) patients, among whom Aspergillus fumigatus was identified for 25 (38%). Histoplasma capsulatum was the responsible pathogen for 15 (6%). The other pathogens identified are listed in the footnote to table 6 .
Minor year-to-year variation in the relative proportion of different fungal species was found, but there was no overall change in the proportion of Aspergillus species to Candida species. There was a relative increase in the proportion of nonalbicans species of Candida to C. albicans species over the 17 years, from 0.75 in 1965-1971 to 1.10 in 1988-1995. The significance of the change in ratio is limited by the small number of patients in the groups.
There is a striking increase in the category of other fungi, including dermatophytes from !10% to about a quarter of all fungi causing FE over the time of the study. With these 47 pathogens, there were strong risk factor associations for previous valve surgery (30 of 47), rheumatic heart disease (17 of 47), antibiotic use (12 of 47), surgery other than cardiac (9 of 47), and immunocompromised patients (8 of 47).
Thirty of the patients had concomitant bacterial infections, of whom 8 (3% of the total) had subacute bacterial endocarditis (SBE), as shown by examination of the valve by means of histological examination, culture, or both. The organisms were Staphylococcus aureus (2 patients), Escherichia coli (1 patient), Serratia marcescens (1 patient), Pseudomonas aeruginosa (1 patient), Streptococcus viridans (1 patient), Staphylococcus epidermidis (1 patient), and Clostridium species (1 patient).
Antifungal and surgical strategies. All patients received medical (antifungal) treatment or surgical treatment or combined medical and surgical treatment or no treatment. The number of patients who had either medical or surgical or medical and surgical treatment was 179; of these, 67 (37%) received systemic antifungal treatment only. Five (3%) received surgery only, and 107 (60%) had combined medical and surgical treatment. Ninety-one (34%) of 270 patients received no treatment for their FE, and 85 of these were diagnosed only at autopsy. In most cases, the correct diagnosis had not been made while the patient was alive, or the patients died at or shortly after admission to hospital.
Of the 112 patients who had surgery as part of their management, 19 (17%) underwent surgery because medical treatment with antifungal therapy failed, 37 (33%) because they had single indications, and 18 (16%) because they had multiple indications; for 38 (34%), the indication for surgery was not stipulated. The single indications were as follows: 11 for FE per se, 9 for the subsequent development of cardiac failure, 10 for subsequent embolization, 6 for subsequent hemodynamic instability, and 1 for persistent sepsis. The multiple indications were as follows: 1 patient had persistent sepsis and FE; 1 patient had cardiac failure and FE; 2 patients had persistent sepsis and hemodynamic instability; 2 patients had cardiac failure and persistent sepsis; 2 patients had persistent sepsis, FE, and subsequent embolization; 5 patients had cardiac failure and he- Preoperative findings and surgical management. The anatomic location of FE was described for 110 patients. The locations were as follows: aortic valve, 68 patients (62%; 35 on the aortic valve alone); mitral valve, 31 (25%; 17 on the mitral valve alone); tricuspid valve, 11 (10%; 8 on the tricuspid valve alone); and pulmonary valve, 2 (2%). Ring abscesses were noted in 18 patients (16%) but always in combination with some other valvular vegetation. Vegetations were described as "large" (but this was not quantified) for 60 (92%) of 65 patients for whom a comment on size was made. The actual sizes in millimeters for the vegetations were recorded for only 17 patients. The most commonly described vegetation was on the aortic valve ( ); these ranged in size from 9-50 mm. Sizes were n p 8 also recorded for mitral ( ), tricuspid ( ), endocarn p 2 n p 3 dium ( ), and ring ( ) vegetations. Valve replacement n p 2 n p 2 was undertaken for 91 (81%) of 112 patients; the remaining patients had valve repair, vegetation excision, or both. Topical amphotericin B irrigation of the cardiac chambers was performed at cardiotomy for 16 (15%) of 110 patients.
Antifungal agents. One hundred seventy-four patients received systemic antifungal agents. The antifungal most commonly administered was conventional amphotericin B. This was given to 162 (93%) of 174 patients. Flucytosine was given to 39 (22%) patients, 5 of whom received it as the sole antifungal. Seven (4%) received one of the following: rifampin, fluconazole, ketoconazole, terbinafine, miconazole, and itraconazole. Very few patients received combination antifungal therapy.
A total of 107 of 174 patients also had valvular surgery; 68 of these received amphotericin B alone and 39 received amphotericin B and flucytosine. Amphotericin B was administered preoperatively for 14 patients, postoperative for 33, and both pre-and postoperative for 50. For 10 patients, the precise timing was not clearly stated. The mean total dose (‫ע‬SD) of amphotericin B was calculable for 28 patients treated preoperatively, and was mg. The mean total dose of am-572 ‫ע‬ 611 photericin B was calculable for 57 patients treated postoperatively, and was mg. Sixty-seven of 174 patients 1422 ‫ע‬ 811 received antifungal agents only. The mean total (‫ע‬SD) dose of amphotericin B was calculable for 36 patients, and was mg.
‫ע‬ 1242
Survival rates associated with treatment, organism, risk factors, and valve site. The crude survival status (patient alive or dead as reported in each publication) was available for 269 patients: 195 (72%) patients died. The cause of death was directly related to FE for 151 (77%) of the 195 deaths, indirectly related to FE for 27 (14%), unrelated to FE for 11 (6%), and was not stated for 6 (3%). Crude survival rates over the 6 There were 167 patients for whom the diagnosis was made before death and for whom the survival (defined as the number of days from first treatment for FE to time of last follow-up or death) was recorded. Patients receiving combined treatment with systemic antifungal agents and surgery tended to have an improved survival rate compared with those receiving medical treatment alone ( figure 2A ). Forty-five (55%) of 102 patients who received combined treatment modalities were alive at 1 year, compared with 21 (36%) of 58 patients who received only antifungal therapy. The differential higher survival was maintained for up to 3 years. The proportion of patients who survived was analyzed according to the 3 most common pathogen groups (Aspergillus, C. albicans, and non-albicans species of Candida; figure 2A ) and by treatment (antifungal agents alone, and antifungal agents plus surgical treatment; proved statistically significant. Survival rates for patients with histoplasmosis were 35% for those treated with antifungal agents and surgery and 63% for those treated with antifungal agents alone. The median duration of survival for patients with Aspergillus infection was 11 days; for those with Candida infection, 690 days; and for those with Histoplasma infection, 540 days ( figure 2B ). Bivariate analyses were conducted on all 19 risk factors to examine their individual associations with survival (x 2 and Fischer's exact tests). Previous valve surgery was found to have a statistically significant association with death ( ). How-P ! .03 ever, a logistic regression analysis that used all 19 risk factors simultaneously found that antibiotic use, immunosuppressive treatment, and previous SBE were all statistically significant ( ), which suggests that they may be all indicators of P ! .05 death. Additional analysis also suggested that age might exert an influence that is different for men than for women.
The survival rate among patients who were given amphotericin B postoperatively was significantly higher than it was among patients who did not receive it: 47 (58%) of 85 patients compared with 6 (48%) of 21 ( , Wilcoxon test), re-P p .01 spectively, were alive at 1-year follow-up examinations. There was no significant difference in the survival rates between the group of patients who received amphotericin B before surgery and the group who did not.
Mortality was highest for patients with mitral valve FE either alone (26 [79%] of 33 patients died) or with concomitant aortic valve FE (6 [60%] of 10 patients died). Patients with solitary aortic valve FE had a 54% mortality rate (25 of 46). The survival rate was best among patients with tricuspid valve FE (8 [89%] of 9 patients survived). The median time of survival for patients with univalvular disease overall was 20 months, and was 5 months for patients with multivalvular FE ( ). P ! .05 Posttreatment complications and FE recurrence. A total of 162 patients survived the initial treatment period. Emboli occurred in 41 (25%) of these 162 patients; 22 (54%) were cerebral, 7 (17%) were in a peripheral limb, 3 (7%) were pulmonary, 3 (7%) were coronary, and 2 (5%) were mesenteric. Major complications from treatment or FE itself were noted in 68 (42%) of 162 patients. Amphotericin B toxicity, flucytosine toxicity, or both was documented in 22 (32%) of 68 patients, prosthetic valve mechanical dysfunction in 11 (16%), nosocomial sepsis in 8 (12%), atrioventricular conduction defects in 7 (10%), and miscellaneous problems in 20 (29%).
FE recurred in 51 (29%) of 162 patients. In 5 (10%) of 51 patients, this was at 12 years of follow-up (treatment had previously been deemed successful for all 5 patients). Suboptimal antifungal therapy (including treatment with 5-fluorocytosine alone, resulting in documented emergence of resistant organisms and gross noncompliance) appeared to be present in 22 of 51 patients.
DISCUSSION
The identification of only 270 high-quality case reports in the English-language world literature over 30 years supports the notion that FE is a rare disease, with fungi responsible !10% of infective endocarditis cases. The objective of this retrospective meta-analysis of selected literature was to provide a template for managing FE by comprehensively describing important profile characteristics, determinants, course, and treatment. We believe it is the largest and most comprehensive review in the last 20 years; it focuses on well-described, authentic reports and is representative of published cases of FE. There is a small possibility that this article fails to reflect a wider picture of FE because of the bias inherent in selecting cases for publication. However, this is unlikely because of the generally accepted rarity of FE (a factor that promoted publication), the large time frame covered, and the low possibility of missing other quality cases in our search. Independent data extraction by 2 investigators minimized crucial errors such as survival duration, and where isolated incomplete information occurred, analyses reflected this.
A proposed major pathogenic component of FE, suggested by animal models, is a prerequisite for valvular anatomic abnormality, including traumatized endothelium [1, 5, [8] [9] [10] [11] , which mediates the formation of a fibrin/platelet bed that allows fungal adhesion. Our findings only give partial support for this hypothesis: only 64% of the patients had previous valve surgery, SBE, or rheumatic heart disease. The lack of concordance between the anatomic site of previous valve surgery and subsequent site of FE, and of predominantly left-side FE occurring in patients with predisposition to right-side endothelial trauma (e.g., injection drug abuse [12] and central lines) is further evidence that suggests pathoetiologic factors other than those suggested from the animal studies are involved in FE genesis. Perhaps the vascular tropism of some fungi, particularly Aspergillus [13] , may override the prerequisite for endothelial trauma in some instances.
Predisposition to an invasive fungal disease is the other important factor. We were able to identify several risk factors consistent with this: injection drug abuse (fungal contamination of drugs), immunosuppressive therapy, neutropenia, or malignancy (reduced anticonidial and antimycelial defenses and lack of integrity of mucosal surfaces), and total parenteral nutrition (contamination). It is remarkable that our review included no patient with hematologic malignancy-one of the highest risks for invasive fungal disease. This may be related to their profound thrombocytopenic status, because platelets play an integral role in the process of the fungus adhering to the vascular endothelium [14] . Recent experience confirms this rare association [15, 16] . Previous use of antibiotics was frequently observed to play a pivotal role (e.g., overgrowth of gastrointestinal Candida because of suppression of normal flora), an indirect role (e.g., use of central iv administration devices), or a surrogate role (e.g., as a marker for FE risk as a result of severe illness, immunosuppressive therapy, or abdominal surgery, because for patients in these groups, concomitant antibiotic use or placement of a central venous catheter are common).
Patients who have had undergone previous valve replacement or valve surgery tend to present with FE earlier than those who have had previous SBE. The late presentation (112 months) of a substantial proportion of these patient groups is a salient reminder that such patients should be closely monitored for several years for early signs of FE.
The changes in risk factors over time, as displayed in figure  1 , are notable. The most striking of these changes-steady increases in the incidence of use of vascular lines and non-cardiac surgery, and increases in the number of immunocompromised patients-reflect the changing hospital patient population; increased exposure to medical technologies deprives patients of adequate mechanical and systemic immune defenses. The parallel decrease in the incidence of rheumatic heart disease underscores the dramatically decreasing incidence of that disease in developed countries [17] . The risk factor with the largest incremental decrease is previous valve surgery, possibly as a result of improvements in surgical technique, better choice of and sterilization of prostheses, and the improvement of the clean-air operating theater environment. Improved policies for the use of antibiotics were introduced in the 1970s and are now followed widely [18] , which could explain the initial decrease in the incidence of the use of antibiotics.
Prominent risk factors are missed or delayed diagnosis, because in the absence of classical signs of infective endocarditis, the signs and symptoms of FE are difficult to distinguish from nonspecific clinical features or are obscured by dominant neuroembolic or febrile phenomena. Even among those patients in whom infective endocarditis was suspected, the etiology was considered bacterial for 111 (41%) of 270. However, diagnostic acumen has significantly improved in recent years. This could reflect the introduction of echocardiography as a diagnostic tool. However, diagnostic delay continues to be reported [19] .
The higher incidence of embolization and of focal or global neurologic dysfunction and the lower incidence of heart failure, changing murmurs, and splenomegaly compared with patients with SBE [20] and large lesions identified via echocardiography indicates that their presence in a patient suspected of having SBE should be regarded as strong circumstantial evidence for FE.
Previous unexplained candidemia was documented for 1 in 10 of the patients in this analysis; 50% did not receive antifungal treatment. Unexplained candidemia should always be fully investigated to determine its source and should be treated if it is associated with fever or other clinical features, even if there is no identifiable lesion [1, 16] . The significance of nosocomial candidemia (for the development of FE) in patients with prosthetic heart valves has been highlighted recently [21] . It may be possible to prevent FE in patients with previous untreated fungemia, particularly if they have other risk factors, by administering preemptive antifungal treatment. In the absence of data, it is unclear whether this group or other risk groups would benefit from such an approach.
There is no information on the risk of developing FE in patients with a single risk factor (e.g., those who are taking antibiotics), but it would appear to be low. Hence antifungal prophylaxis for these patients would be inappropriate. Patients who have unique combinations of risk factors (e.g., complex abdominal surgery, prolonged treatment with antibiotics, known valvular dysfunction, and a high degree of mucosal fungal colonization) may be a group that would merit inclusion in a study of the efficacy of prophylaxis or preemptive treat- Recommendations for the diagnosis and management of fungal endocarditis (FE) .
Category Recommendation
Suspicion FE should be highly suspected for middle-aged men with either (a) known preexisting valvular disease and asymptomatic fungemia; or (b) у1 major stem risk factor for FE (in particular, previous valve surgery, bacterial endocarditis, rheumatic heart disease) and fever, changed heart murmurs, major neural or neuroembolic phenomena and negative findings of bacterial culture Diagnosis Diagnosis should be made early by use of high diagnostic suspicion and acumen supported by the following: (a) transthoracic or transesophageal echocardiography that demonstrates large, bulky vegetations; (b) positive findings of culture of peripheral blood and/or accessible emboli specimens or histologic examination of accessible emboli; and (c) positive findings from fungal antigen and antibody detection systems (which should be used routinely for diagnosis of high-risk patients in a validation setting)
Management Early combination antifungal medication and valve replacement for optimal success; antifungal agents should be used early, in high dosages; amphotericin B is the drug of choice, but it should be administered as a lipid preparation to optimize continued uninterrupted therapy and reduce toxicity. Optimal dosage, timing, and duration of treatment is undetermined, but basic antifungal therapeutics direct that treatment is given preoperatively, perioperatively and postoperatively, aiming for an acute delivery load of 2-3 g. Careful, prolonged follow-up on secondary prophylaxis aided by serologic testing (requires validation) should be performed to detect the possibility of early fungal recurrence. Secondary prophylaxis should be for a minimum of 2 years, with fluconazole for susceptible Candida species and itraconazole-cyclodextrin or voriconazole for Aspergillus species.
ment. Prospective studies of prophylaxis would probably require extremely large numbers of patients to demonstrate any advantage. Laboratory-microbiologic fungal diagnosis was best achieved by means of histologic examination of removed valve vegetations (95% sensitive for a fungal diagnosis), whereas examination of accessible emboli was less sensitive. Blood cultures proved the least sensitive, at 54%. Precise identification of the pathogenic organism was more often achieved for Candida than for Aspergillus species, in part reflecting the difficulty of distinguishing Aspergillus species from each other and from some other non-Aspergillus molds by histological examination and the high insensitivity of blood culture for Aspergillus species.
Clearly there is scope for improvement in diagnostic acumen. The diagnosis of FE should be aggressively pursued, particularly for a patient with the following characteristics: (1) valvular disease, (2) suspected diagnosis of SBE, (3) unexplained neurologic signs, (4) peripheral embolization (5) negative results of blood cultures, and (6) recent documented but untreated fungemia. Diagnostic tests should include fungal blood cultures, mycologic examination of accessible emboli, echocardiography, and appropriate fungal antigen and nucleic acid diagnostic tests. There have been major advances in detecting anti-Candida immunoglobulin, Candida mannan, fungal wall glucan, and Aspergillus galactomannan with sensitivities and specificities of 180% in other patient populations, and this requires validation in the diagnosis of FE [22] .
We found a higher proportion of patients with FE caused by Candida species than by Aspergillus species, a finding in keeping with other reports [1, 5] . Insufficient data were provided in the reviewed papers to comment on community-acquired or nosocomial modes of acquisition of FE. Aspergillus endocarditis did not usually occur in the setting of disseminated aspergillosis. Two cases were traced to contaminated bioprosthetic valves, and another was linked to gross contamination of the air in the operating theater. In contrast, Histoplasma endocarditis was one manifestation of established histoplasmosis.
The slight increasing proportion of non-albicans species of Candida to C. albicans species over the years is consistent with the reported emergence of non-albicans species of Candida as a significant fungal pathogen in other settings [23, 24] . This may have arisen as a result of selective pressure due to use of azoles, socioepidemiologic changes such as the increase in injection drug abuse, and increases in the use of high-technology treatments. Although the pathogenicity of some non-albicans species of Candida has been questioned, the data leave no doubt over their clinical significance.
It is curious that the increase in the incidence of FE caused by recently-emerged pathogens is associated with a decrease in the overall incidence of risk factors, apart from risk factors seen in immunocompromised patients. This might be accounted for by a change in the pool of fungal pathogens or by hidden changes in the character or management of the risk factors.
Management of FE is inconsistent. The majority of treated patients received systemic antifungal agents, usually amphotericin B, but only 63% also had surgical valve replacement, and of these, !20% underwent surgery primarily for FE. With the exception of patients infected with Histoplasma, patients with FE who have fungal etiologies that are treated with both medical and surgical interventions have a significantly better chance of survival than do patients who receive medical treatment alone. This does not necessarily mean that a combined approach directly improves the chance of survival. An alternative explanation is that patients proceeding to surgery have been selected for a better outcome, perhaps because their general condition is better. Yet there are theoretical reasons to favor a combined medical-surgical approach. Histological examination has revealed lesions of established FE comprising large vegetations that have protective biofilms [25, 26] , which raises concern about whether antifungal drugs can be effectively delivered, and hence doubt about the efficacy of antifungal treatment alone. Indeed, documented cures of FE treated solely with systemic antifungal agents are rare [27] . These cases are usually in patients with Candida endocarditis [28, 29] . Recent publications from single centers advocate a combined medicalsurgical approach. The surgical component includes radical surgical debridement and replacement of the valve with biologic material, whereas the medical component uses perioperative systemic antifungal agents and prolonged postoperative antifungal treatment [30] [31] [32] .
Antifungal therapy could fail for other reasons. The prevalence of suboptimal dosing is underscored by the wide variation in amphotericin B dosage, the high frequency of reduced compliance with amphotericin B regimens because of toxicity, and treatment with 5-fluorocytosine alone. The availability of lipidassociated amphotericin B in recent years, which has a high therapeutic index, should obviate these therapeutic deficiencies. Lipid-associated amphotericin B allows the high and prolonged dosage necessary, on empirical grounds, to optimize the drug's delivery into bulky vegetations, to adequately treat emboli, and to reduce seeding of target organs via the hematogenous route [33] . It is of some interest that combinations of antifungal agents were infrequently used. The importance of close followup after successful treatment of FE is shown by the late relapse of several patients who were initially deemed cured. More recent publications confirm the high rate of relapse (30%-40%) [30, 31] , which can occur up to 9 years later [34] , and the need for secondary antifungal prophylaxis.
Candida etiology seems to be associated with improved rates of survival when compared with Aspergillus etiology. A small series of 12 patients, most of whom had Candida FE and none Aspergillus, had an overall survival rate of 67% [31] .
Our findings suggest a trend to improved outcome over recent years. There are at least 3 explanations for this trend. First, the introduction of echocardiography as a diagnostic tool in the mid-1970s and the recognition of the significance of large vegetations (37 of 39 patients in our review) have probably been major factors. Indeed, these developments coincided with the sudden improvement in the survival rate for patients with FE (from 13%-15% before 1974, to 24% at the time when echocardiography came into widespread use, to 130% after 1979). Second, our observation that diagnostic acumen for FE has significantly improved, such that more cases are diagnosed before surgery, is also notable, and it probably gained valuable therapeutic time for the patients. Finally, in recent years, supportive care of severely ill patients in intensive care units has improved in general. During the period of this study, there has been no widespread use of new antifungal drugs. The recent arrival of the lipid-associated compounds, such as lipid-associated amphotericin B (AmBisome; Gilead Sciences), may improve therapeutic outcome, if the experience with other invasive mycoses [34] is reproduced for FE.
Clarification of these crucial management issues by performance of randomized, prospective, comparative clinical trials in humans may be seriously compromised by the difficulties inherent in performing such studies given the rarity of FE, the demographic heterogeneity of the patient population, and the frequency of delayed diagnosis. A feasible alternative might be to notify a single data surveillance unit about any patients who have FE, and include high-quality clinical and management details to facilitate subsequent analysis. Expert panel-generated consensus management guidelines are required; these should address the choice of antifungal agents and their dosage, the timing of surgery, and follow-up. In the meantime, the essential therapeutic elements appear to be combined medical and surgical treatment that involves both pre-and postoperative lipidassociated amphotericin B (for improved compliance and to allow for higher doses), valve replacement as soon as the diagnosis is suspected, prolonged (perhaps lifelong) postoperative antifungal therapy, and prolonged medical surveillance to detect relapse. These recommendations are summarized in table 8.
